Kidney & Blood Pressure Research · 2012 · 79 citations · 19 references
MedicineEndocrinologyNephrologyExcretionRenal PathologyRenal PathophysiologyDiabetes MellitusDiabetic NephropathyRenal DiseaseRenal ExcretionRenal ImpairmentUrinary ExcretionProteinuria ReductionRenal Microvascular InjuryRenoprotective EffectsRenoprotective TherapiesType Iv Collagen
<b><i>Aims:</i></b> It was reported that exenatide ameliorated renal injury in diabetic rats. The present study was carried out to evaluate the effect of exenatide on 24-hour urinary albumin, urinary transforming growth factor-β<sub>1</sub> (TGF-β<sub>1</sub>) and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. <b><i>Methods:</i></b> 31 type 2 diabetic patients with microalbuminuria were randomly allocated to receive exenatide (group Exe, n = 13) or glimepiride treatment (group Glm, n = 18) for 16 weeks. Body mass index (BMI), fasting plasma glucose, 2-hour postprandial plasma glucose, glycated hemoglobin A<sub>1c</sub>, systolic blood pressure, diastolic blood pressure, 24-hour urinary albumin, urinary TGF-β<sub>1</sub> and type IV collagen concentration were analyzed between the two treatment groups. 20 age- and BMI-matched healthy subjects were chosen as the normal control group (group NC, n = 20). <b><i>Results:</i></b> After 16 weeks of treatment, 24-hour urinary albumin, urinary TGF-β<sub>1</sub> and type IV collagen in group Exe were significantly lower than those of group Glm (p < 0.01), while glycemic control had no statistical difference between<b> </b>the two groups. <b><i>Conclusions:</i></b> Our results indicate that exenatide reduces urinary TGF-β<sub>1</sub> and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria, which may be partly contributory to its directly renoprotective role.
19
Prevalence of Diabetes among Men and Women in China
Wenying Yang, Juming Lu, Jianping Weng et al. · New England Journal of Medicine · 2010 · 3.1K citations